Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

被引:3
作者
De, Sourav [1 ]
Kuo, Yung-Chih [1 ,2 ]
机构
[1] Natl Chung Cheng Univ, Dept Chem Engn, Chiayi 62102, Taiwan
[2] Natl Chung Cheng Univ, Adv Inst Mfg High Tech Innovat, Chiayi 62102, Taiwan
关键词
Nanocarrier; Diabetes mellitus; Drug delivery; Parkinson's disease; GLUCAGON-LIKE PEPTIDE-1; SOLID LIPID NANOPARTICLES; CENTRAL-NERVOUS-SYSTEM; LEVODOPA METHYL ESTER/BENSERAZIDE; SUBCHRONIC INTRAMUSCULAR TOXICITY; ROTIGOTINE-LOADED MICROSPHERES; SENSITIVE POTASSIUM CHANNELS; SALSOLINOL-LIKE COMPOUND; DOPAMINERGIC-NEURONS; INSULIN-RESISTANCE;
D O I
10.1016/j.jtice.2024.105401
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Background: The connection between type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD) was first pointed out in the early 1960s. This probable link is still under serious consideration nowadays. Methods: Neurological changes caused by T2DM could be relevant to PD that included neuroinflammation, dopaminergic deregulation, reduction in the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, increment in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 and acceleration of alpha-synuclein (alpha-Syn) amyloid fibril formation. Furthermore, medical evidence disclosed that significantly exacerbated PD symptoms were associated with the initiation of T2DM, and common genes were concurrently found in DNA of T2DM and PD patients. Insulin resistance and microbiota dysbiosis of the gut-brain axis also connected DM to PD, explaining DM could be a risk factor for PD. In terms of treatment, antidiabetic drugs appeared to engender a certain degree of neuroprotective activity against PD. During drug delivery to the central nervous system, biomaterials could play a crucial role in permeating the blood-brain barrier (BBB) and recognizing exact cerebral tissue to rescue neurons from degeneration. Exosomes, liposomes, micelles, solid lipid nanoparticles, dendrimers, niosomes and nano-sized polymers have been developed to enhance drug and gene efficacy in brain targeting for PD management. In order to boost BBB permeability and alpha-Syn conjugation, the surface of these nanocarriers (NCs) were modified with active biomolecules, for instance, lactoferrin, angiopep and OX26. Natural exosomes were exposed to a limited number, and can be an efficient vector in analyzing the pathways from DM toward PD for clinical trials. Significant findings: This review focuses on understanding the pathophysiological relation between T2DM and PD, and the treatment for the two diseases with NCs. We also highlight the problems that have been solved and the challenges that continue.
引用
收藏
页数:17
相关论文
共 290 条
[1]   Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2 antioxidant signaling pathways [J].
Abdelsalam, Rania M. ;
Safar, Marwa M. .
JOURNAL OF NEUROCHEMISTRY, 2015, 133 (05) :700-707
[2]   Insulin prevents aberrant mitochondrial phenotype in sensory neurons of type 1 diabetic rats [J].
Aghanoori, Mohamad-Reza ;
Smith, Darrell R. ;
Chowdhury, Subir Roy ;
Sabbir, Mohammad Golam ;
Calcutt, Nigel A. ;
Fernyhough, Paul .
EXPERIMENTAL NEUROLOGY, 2017, 297 :148-157
[3]   Carboxymethyl cellulose coated magnetic nanoparticles transport across a human lung microvascular endothelial cell model of the blood-brain barrier [J].
Aguilera, Gabriela ;
Berry, Catherine C. ;
West, Rachel M. ;
Gonzalez-Monterrubio, Enrique ;
Angulo-Molina, Aracely ;
Arias-Carrion, Oscar ;
Angel Mendez-Rojas, Miguel .
NANOSCALE ADVANCES, 2019, 1 (02) :671-685
[4]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[5]  
2-S
[6]   FDA-approved poly(ethylene glycol)-protein conjugate drugs [J].
Alconcel, Steevens N. S. ;
Baas, Arnold S. ;
Maynard, Heather D. .
POLYMER CHEMISTRY, 2011, 2 (07) :1442-1448
[7]   Gold nanoparticle-based colorimetric biosensors [J].
Aldewachi, H. ;
Chalati, T. ;
Woodroofe, M. N. ;
Bricklebank, N. ;
Sharrack, B. ;
Gardiner, P. .
NANOSCALE, 2018, 10 (01) :18-33
[8]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[9]  
[Anonymous], 2018, NeuroPharmac J
[10]   Metal-Based Nanoparticle Magnetic Resonance Imaging Contrast Agents: Classifications, Issues, and Countermeasures toward their Clinical Translation [J].
Antwi-Baah, Ruth ;
Wang, Yajing ;
Chen, Xiaoqin ;
Yu, Kui .
ADVANCED MATERIALS INTERFACES, 2022, 9 (09)